ThyroSeq (v2) Next Generation Sequencing Lab Testing Services to Detect Thyroid cancers

Added: Apr 14, 2017 7:03 am Page 1 of 1

Page 1 of 1

Pre-Solicitation Notice for notice of intent to award a sole source contract. This is not a solicitation. The Department of Veterans Affairs intends to negotiate a sole source contract for a 12 month base and (4) annual option years to obtain Thyroseq (v2) Next Generation Sequencing Testing Services from CBL Path, Inc., 760 Westchester Ave., Rye Brook, NY 10573. This test was developed by the University of Pittsburgh Medical Center (UPMC) to detect point mutations and gene fusion in more than 60 genes associated with thyroid cancer. The test will provide VA practitioners with insight into therapeutic efficacy based on the profile of the cancer. CBL Path, Inc. has an exclusive agreement with UPMC to be the sole provider of this test. Since the intent is to procure this on a sole source basis, no solicitation will be posted to FedBizOps (FBO). A Sources Sought Notice was published to FBO on 2/3/2017 with no responses other than CBL Path. The applicable NAICS code is 621511. The FSC/PSC is Q301. The authority for this action is FAR 6.302.1-1 Only One Responsible source and no other supplies or services will satisfy agency requirements.

Interested persons may contact the Contracting Officer via email at Valerie.DeAngelis@va.gov regarding this procurement. The determination to conduct a competitive procurement based on responses to this notice is solely within the discretion of the Contracting Officer.